Longeveron's Q1 2026: New CEO, Partnerships, and August Data

Longeveron, under new CEO Stephen Willard, has released its Q1 2026 earnings, focusing on partnerships for its stem cell therapy Lomecel-B. The company shifted to a leaner model, securing cash from Coastland Capital and Janus Henderson. The phase two b ELPIS two trial for hypoplastic left heart syndrome in infants will provide top-line data in August 2026. The FDA rejected right ventricle ejection fraction as the main endpoint, pushing for hard stats like all-cause mortality, transplant-free survival, and major cardiac events. Longeveron plans to submit a stats plan and meet again post-data to map a path to a biologics license application. The company also has a phase two trial for pediatric dilated cardiomyopathy planned for 2027. Longeveron aims to secure partnerships to speed value, with August data potentially transforming its position. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e4785faf73c54331